Immune reconstitution inflammatory syndrome: Risk factors and treatment implications

Yukari C Manabe, James D. Campbell, Emily Sydnor, Richard D Moore

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Immune reconstitution inflammatory syndrome (IRIS), also called immune restoration disease, occurs in a subset of HIV-infected patients after the initiation of highly active antiretroviral therapy (HAART) and can be diagnostically challenging and difficult to treat. We sought to determine clinical risk factors for the development of IRIS. METHODS: Patients from the Johns Hopkins HIV Clinic who had IRIS were identified and matched with 4 controls without IRIS who had initiated HAART within 6 months of the case. RESULTS: Forty-nine cases of IRIS were identified; patients presented a median of 29 days from the initiation of HAART (range: 4 to 186 days). A multivariate analysis showed that the development of IRIS was independently associated with using a boosted protease inhibitor (BPI) (odds ratio [OR] = 7.41; P = 0.006), a nadir CD4 count

Original languageEnglish (US)
Pages (from-to)456-462
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume46
Issue number4
DOIs
StatePublished - Dec 2007

Fingerprint

Immune Reconstitution Inflammatory Syndrome
Highly Active Antiretroviral Therapy
Therapeutics
HIV
Immune System Diseases
CD4 Lymphocyte Count
Protease Inhibitors
Multivariate Analysis
Odds Ratio

Keywords

  • AIDS
  • HIV
  • Immune reconstitution disease
  • Immune reconstitution inflammatory syndrome
  • Paradoxical worsening
  • Steroids

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Immune reconstitution inflammatory syndrome : Risk factors and treatment implications. / Manabe, Yukari C; Campbell, James D.; Sydnor, Emily; Moore, Richard D.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 46, No. 4, 12.2007, p. 456-462.

Research output: Contribution to journalArticle

@article{e588fcbfcd004c378a61b1293ef1aa7b,
title = "Immune reconstitution inflammatory syndrome: Risk factors and treatment implications",
abstract = "BACKGROUND: Immune reconstitution inflammatory syndrome (IRIS), also called immune restoration disease, occurs in a subset of HIV-infected patients after the initiation of highly active antiretroviral therapy (HAART) and can be diagnostically challenging and difficult to treat. We sought to determine clinical risk factors for the development of IRIS. METHODS: Patients from the Johns Hopkins HIV Clinic who had IRIS were identified and matched with 4 controls without IRIS who had initiated HAART within 6 months of the case. RESULTS: Forty-nine cases of IRIS were identified; patients presented a median of 29 days from the initiation of HAART (range: 4 to 186 days). A multivariate analysis showed that the development of IRIS was independently associated with using a boosted protease inhibitor (BPI) (odds ratio [OR] = 7.41; P = 0.006), a nadir CD4 count",
keywords = "AIDS, HIV, Immune reconstitution disease, Immune reconstitution inflammatory syndrome, Paradoxical worsening, Steroids",
author = "Manabe, {Yukari C} and Campbell, {James D.} and Emily Sydnor and Moore, {Richard D}",
year = "2007",
month = "12",
doi = "10.1097/QAI.0b013e3181594c8c",
language = "English (US)",
volume = "46",
pages = "456--462",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Immune reconstitution inflammatory syndrome

T2 - Risk factors and treatment implications

AU - Manabe, Yukari C

AU - Campbell, James D.

AU - Sydnor, Emily

AU - Moore, Richard D

PY - 2007/12

Y1 - 2007/12

N2 - BACKGROUND: Immune reconstitution inflammatory syndrome (IRIS), also called immune restoration disease, occurs in a subset of HIV-infected patients after the initiation of highly active antiretroviral therapy (HAART) and can be diagnostically challenging and difficult to treat. We sought to determine clinical risk factors for the development of IRIS. METHODS: Patients from the Johns Hopkins HIV Clinic who had IRIS were identified and matched with 4 controls without IRIS who had initiated HAART within 6 months of the case. RESULTS: Forty-nine cases of IRIS were identified; patients presented a median of 29 days from the initiation of HAART (range: 4 to 186 days). A multivariate analysis showed that the development of IRIS was independently associated with using a boosted protease inhibitor (BPI) (odds ratio [OR] = 7.41; P = 0.006), a nadir CD4 count

AB - BACKGROUND: Immune reconstitution inflammatory syndrome (IRIS), also called immune restoration disease, occurs in a subset of HIV-infected patients after the initiation of highly active antiretroviral therapy (HAART) and can be diagnostically challenging and difficult to treat. We sought to determine clinical risk factors for the development of IRIS. METHODS: Patients from the Johns Hopkins HIV Clinic who had IRIS were identified and matched with 4 controls without IRIS who had initiated HAART within 6 months of the case. RESULTS: Forty-nine cases of IRIS were identified; patients presented a median of 29 days from the initiation of HAART (range: 4 to 186 days). A multivariate analysis showed that the development of IRIS was independently associated with using a boosted protease inhibitor (BPI) (odds ratio [OR] = 7.41; P = 0.006), a nadir CD4 count

KW - AIDS

KW - HIV

KW - Immune reconstitution disease

KW - Immune reconstitution inflammatory syndrome

KW - Paradoxical worsening

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=36049048260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36049048260&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e3181594c8c

DO - 10.1097/QAI.0b013e3181594c8c

M3 - Article

C2 - 18077835

AN - SCOPUS:36049048260

VL - 46

SP - 456

EP - 462

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 4

ER -